Stilbeneflavone type compounds and preparation methods and pharmaceutical uses thereof

The antibiotic resistance of multidrug-resistant Staphylococcus aurepen A-D and alopecron N were solved by targeting the external pump protein targets of multidrug-resistant Staphylococcus aureus by using diphenyl and dihydroflavone-type compounds alopecron A-D and alopecron N isolated from the Chinese herbal bitter beans. The sexual problem has achieved significant antibacterial effect on a variety of drug-resistant bacteria species.

CN114763359BActive Publication Date: 2024-11-01FUDAN UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202110057462.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-01-15
Publication Date
2024-11-01
Estimated Expiration
2041-01-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the antibiotic resistance problem of multidrug-resistant Staphylococcus aureus, especially because bacteria pump antibiotics out of the cells through the external pump protein system, resulting in a decrease in the concentration of antibiotics and unable to effectively inhibit infection.

Method used

The obtained diphenyl and dihydroflavone type compounds alopecurone A-D and alopecurone N isolated and purified from the Chinese herbal bitter beans were prepared with significant antibacterial through external pump protein targets such as MsrA, NorA, and TetK in multidrug-resistant Staphylococcus aureus, such as MsrA, NorA, and TetK, which are used to treat multidrug-resistant Staphylococcus aureus, to prepare significant antibacterial protein targets such as MsrA, NorA, and TetK in the multidrug-resistant Staphylococcus aureus. The drug of action.

Benefits of technology

The compounds show significant antibacterial effects on a variety of multidrug-resistant Staphylococcus aureus species, especially for bacteria with different external pump resistance mechanisms, with a minimum antibacterial concentration of 1-2mg/L, providing a new antibacterial resistance. Drug selection for multidrug-resistant Staphylococcus aureus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure BDA0002901305030000021
    Figure BDA0002901305030000021
  • Figure BDA0002901305030000041
    Figure BDA0002901305030000041
Patent Text Reader

Abstract

The present invention belongs to the field of pharmaceutical technology, and relates to stilbene-flavone type compounds and their pharmaceutical uses, and in particular to a preparation method of stilbene-flavone type compounds alopecuroneA-D and alopecuroneN in the Chinese herbal medicine Sophora alopecura and their use in preparing drugs and preparations against multidrug-resistant Staphylococcus aureus. The stilbene-flavone structure type compounds of the present invention have significant inhibitory effects on six types of Staphylococcus aureus, including five types of exo-pump-resistant Staphylococcus aureus, and can be used to prepare antibacterial drugs in various dosage forms including injections, oral drugs and topical drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical technology and relates to stilbene flavonoid compounds and pharmaceutical uses thereof, in particular to a preparation method of stilbene flavonoid compounds alopecurone AD and alopecurone N in a Chinese herbal medicine Sophora alopecura and their use in preparing drugs and preparations against multidrug-resistant Staphylococcus aureus. Background Art

[0002] The prior art discloses that bacterial resistance is still a problem that plagues clinical infection treatment. Among them, multidrug-resistant Staphylococcus aureus has become the most common serious infection pathogen in hospitals. Studies have shown that in addition to being resistant to all beta-lactam antibiotics, this pathogen has also developed resistance to macrolides, fluquinoxaline, tetracycline and other types of antibiotics. [1] According to research, the widespread use and even abuse of antibiotics in my country in recent years has led to an increasingly severe bacterial resistance situation. Therefore, while limiting the abuse of antibiotics to slow down the growth of resistant strains, research on new types and new mechanisms of drugs against multidrug-resistant Staphylococcus aureus has attracted attention in this field.

[0003] Studies have shown that methicillin-resistant Staphylococcus aureus has multiple drug resistance mechanisms, one of the most important and common bacterial resistance mechanisms is the active efflux mechanism, which is the active excretion process of pumping drugs out of the cell mediated by various efflux protein systems. In addition to having a 40kb chromosomal resistance gene (mecA) that encodes methicillin binding protein (PBP) to produce β-lactam resistance, Staphylococcus aureus also produces resistance to macrolides, fluquinoxaline, tetracycline and quaternary ammonium salts through MsrA [2] ,NorA [3] ,TetK [4] and QacA [5] Efflux proteins form an efflux resistance mechanism. Bacterial cells use efflux pumps to pump most commonly used antibiotics out of the cell, reducing the concentration of antibiotics in the cell and making them ineffective in antibacterial effects.

[0004] The Chinese herbal medicine Sophora alopecuroides is a plant of the genus Sophora in the Leguminosae family. Both the root and the whole plant can be used as medicine. It is mainly distributed in the desert and semi-desert areas in northern China. Its traditional effects include clearing away heat and dampness, relieving pain, and killing insects. Modern pharmacological studies have shown that Sophora alopecuroides has antiviral, anti-inflammatory, and anti-tumor pharmacological effects.

[0005] Based on the foundation and current status of the prior art, the inventors of this application intend to provide a method for preparing stilbene-flavone-type compounds and their pharmaceutical uses, especially alopecurone AD and alopecurone N, stilbene-flavone-type compounds in the Chinese herbal medicine Sophora alopecura, and their use in preparing drugs and preparations against multidrug-resistant Staphylococcus aureus. The present invention uses natural products as an important source of new chemical entities, providing valuable resources for finding and discovering new antibacterial drugs.

[0006] References

[0007] [1]Li TM, Song Y, Zhu YJ, Du

[0008] [2] Ross JI, Eady EA, Cove JH, Cunliffe WJ, Baumberg S, WoottonJC. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. MolMicrobiol. 1990, 4(7): 1207-1214.

[0009] [3]Ng EY, Trucksis M, Hooper DC. Quinolone resistance mediated by norA:physiologic characterization and relationship to flqB, a quinolone resistancelocus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother. 1994, 38(6): 1345-1355.

[0010] [4]Guay GG,Khan SA,Rothstein DM.The tet(K)gene ofplasmidpT181ofStaphylococcus aureus encodes an efflux protein that contains14transmembrane helices.Plasmid.1993,30(2):163-166.

[0011] [5]Marshall NJ, Piddock LJ. Antibacterial effluxsystems.Microbiologia.1997,13(3):285-300. Summary of the invention

[0012] The purpose of the present invention is to provide a method for preparing a stilbene-flavone-type compound and alopecurone N in a Chinese herbal medicine Sophora flavescens and their application in preparing drugs and preparations against multidrug-resistant Staphylococcus aureus based on the basis and status of the prior art.

[0013] In the present invention, the dihydroflavonoid compounds having the following stilbene dihydroflavonoid chemical structure are prepared by separating and purifying the ethanol extract of the root of Sophora alopecuroides L. from the Chinese herbal medicine:

[0014]

[0015] The hydroxyphenyl group on the five rings of tetrahydrofuran in the structure is α- or β-oriented, and R2 in the structural formula is -H or isopentenyl.

[0016] More specifically, in the present invention, the ethanol extract of the root of Sophora alopecuri was separated and purified and the synergistic antibacterial activity was tested to obtain the stilbene-flavone-type compounds alopecurone A-D and alopecurone N with significant antibacterial effects. The present invention selects multidrug-resistant Staphylococcus aureus with exo-pump proteins such as MsrA, NorA, and TetK as targets, and can further prepare drugs with anti-exo-pump type resistant Staphylococcus aureus.

[0017] The invention has been experimentally verified that the natural stilbene flavonoid type compounds alopecurone AD and alopecurone N separated from the Chinese herbal medicine Sophora alopecuroides have significant inhibitory effects on six Staphylococcus aureus species. Among them, the minimum inhibitory concentration (MIC) of the compound alopecurone AC against six Staphylococcus aureus strains SA1199B (containing norA efflux pump gene), XU212 (containing TetK efflux gene), ATCC25923, RN4220 (containing MsrA efflux gene), EMRSA-15 (containing MecA resistance gene) and EMRSA-16 (containing MecA resistance gene) was 1 mg / L; the MIC of the compound alopecurone D against strains RN4220 and EMRSA-16 was 2 mg / L, and the MIC for the other four strains was 1 mg / L; the MIC of the compound alopecurone N against strains ATCC25923 and RN4220 was 1 mg / L, and the MIC for the other strains was 2 mg / L.

[0018] The present invention provides a method for separating, purifying and identifying stilbene-dihydroflavone type compounds:

[0019] Sophora alopecuroides root (5.5 kg) was extracted by heating with ethanol, concentrated to obtain an extract, and extracted with ethyl acetate to obtain an extract (196 g). The extract was separated and purified by repeated silica gel column chromatography (chloroform-ethyl acetate, chloroform-acetone system), gel column chromatography (chloroform-methanol system) and reversed-phase silica gel column chromatography (methanol-water system) to obtain alopecurone A 89 mg, alopecurone B 75 mg, alopecurone C 6 mg, alopecurone D 2 mg, alopecurone N 8 mg;

[0020] In the present invention, the ethyl acetate extraction part of the 95% ethanol extract of Sophora alopecuroides is subjected to silica gel column chromatography, and the obtained compound after purification is dissolved in deuterated acetone for nuclear magnetic resonance, and dissolved in methanol for mass spectrometry structure testing; in the present invention, the silica gel column chromatography separation of the compound uses silica gel of 200-300 mesh and 300-400 mesh, and the solvent is dichloromethane-methanol (95:5-8:2) and chloroform-methanol (9:1); the ODS reverse phase silica gel column chromatography elution solvent is methanol-water (7:3).

[0021] The chemical structural formula of the stilbene dihydroflavonoids separated and prepared by the present invention is shown as follows:

[0022]

[0023] The present invention carried out bacterial culture and compound antibacterial effect test:

[0024] The direct antibacterial effect experiment of the compound described in the present invention is carried out on a clean bench in a cell culture room, and bacteria are cultured in a 96-well plate, with Mueller-Hinton Broth (MHB) as a culture medium; appropriate amounts of the compound sample to be tested and the antibiotic ofloxacin are taken, dissolved in DMSO to prepare a mother solution of a certain concentration, diluted with broth to a certain concentration and added to the 96-well plate for equal dilution, and no drug is added as a negative control, and then bacteria are inoculated in the 96-well plate, placed in an incubator at 37°C and cultured for 24 hours, MTT is added, and the results are observed, and the minimum concentration of the drug required when the bacteria do not grow at all is taken as the MIC value of the drug for this bacterial species, and MTT solution 3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium blue bromide (Sigma) is used to detect the growth of bacteria, and the change of MTT from yellow to blue indicates bacterial growth.

[0025] In the present invention, the concentration of drug-resistant Staphylococcus aureus in the anti-resistant bacteria activity experiment is 5×10 5 cfu / mL; the concentrations of the experimental compound and the positive control drug ofloxacin were 0.25-128 mg / L.

[0026] In the present invention, the direct antibacterial effect experimental results show that the compounds alopecurone AD and alopecurone N have significant direct antibacterial effects on six bacterial species, with MIC of 1-2 mg / L, proving that the compounds have anti-drug-resistant Staphylococcus aureus infection effects.

[0027] The invention has been experimentally confirmed that the natural stilbene flavonoid type compounds alopecurone AD and alopecurone N separated from the Chinese herbal medicine Sophora alopecurus have significant inhibitory effects on six Staphylococcus aureus species and can be further used to prepare drugs for Staphylococcus aureus with anti-exo-pump type resistance. DETAILED DESCRIPTION

[0028] The present invention will now be further described in conjunction with embodiments, but the implementation of the present invention is not limited thereto.

[0029] The roots of bitter bean (Sophora alopecuroides) used in the examples were collected from Shihezi, Xinjiang.

[0030] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods in the art.

[0031] Unless otherwise specified, the materials and reagents used in the following examples were obtained from commercial sources.

[0032] Example 1. Compound separation and purification

[0033] Sophora alopecuroides root (5.5 kg) was extracted with 95% ethanol by heating (45°C), and concentrated under vacuum to obtain 600 g of extract, which was extracted and concentrated with ethyl acetate to obtain 196 g of ethyl acetate extract. The ethyl acetate extract was subjected to silica gel column chromatography (200-300 mesh), and gradient elution was performed using dichloromethane-methanol (99:1-9:1) to obtain Fr.1-Fr.15; component Fr.9 (25 g) was subjected to silica gel column chromatography (dichloromethane-methanol 95:5-8:2) to obtain Fr.9.1 to Fr.9.5. Component Fr.9.4 was separated and purified by gel column chromatography (sephadex LH-20), silica gel column chromatography (300-400 mesh, chloroform-methanol 9:1) and ODS reverse phase silica gel column chromatography (methanol-water 7:3) to obtain compounds alopecurone C (6 mg), alopecurone D (2 mg) and alopecurone N (8 mg); component Fr.10 (200 mg) was separated and purified by ODS reverse phase silica gel column chromatography (methanol-water 7:3) to obtain compounds alopecurone A (89 mg) and alopecurone B (75 mg). All monomer compounds were analyzed by HPLC (methanol: water = 7:3) with a purity greater than 98.0%.

[0034] Example 2. Direct anti-drug resistant bacterial activity of stilbene-flavone type compounds

[0035] The direct antibacterial effect test of the five stilbene-dihydroflavonoid compounds and ofloxacin was carried out according to the above direct antibacterial test method.

[0036] The experimental bacteria SA1199B is Staphylococcus aureus that overexpresses NorA multidrug resistance external pump protein, the experimental bacteria XU212 is Staphylococcus aureus that overexpresses TetK multidrug resistance external pump protein, the experimental bacteria ATCC25923 is a model strain, the experimental bacteria RN4220 is Staphylococcus aureus that overexpresses MsrA multidrug resistance external pump protein, and the experimental bacteria EMRSA-15 and EMRSA-16 are multidrug resistant Staphylococcus aureus that overexpress MecA gene. The experimental results show that the five compounds of the present invention have significant direct antibacterial effects on six Staphylococcus aureus species (as shown in Table 1).

[0037] Table 1. Minimum inhibitory concentration (MIC) of compounds and antibiotic ofloxacin against drug-resistant bacteria

[0038]

Claims

1. Use of stilbene dihydroflavonoid compounds in the preparation of drugs against drug-resistant bacteria; the drug-resistant bacteria are drug-resistant Staphylococcus aureus strains SA1199B, XU212, RN4220, EMRSA-15 and / or EMRSA16; The stilbene dihydroflavonoid compound has the following structure: 。 2. The use according to claim 1, It is characterized in that The stilbene flavonoids are prepared by the following method: the roots of Sophora alopecuroides are heated and extracted with ethanol, concentrated to obtain an extract, and extracted with ethyl acetate to obtain an extract. The extract is separated and purified by repeated silica gel column chromatography, gel column chromatography and reversed phase silica gel column chromatography to obtain the compound of claim 1.

Citation Information

Patent Citations

  • Method for quickly separating and preparing natural dihydroflavonoid compounds by using high-speed counter-current chromatography

    CN107652260A